Siena Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Siena Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	-$8K	–	214
2022 Q2	$8K	Hold	50	–	–	﹤0.01%	183
2022 Q1	$8K	Buy	+50	New	+$7.26K	﹤0.01%	225

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Siena Capital's JAZZ Position: Q3 2022 in Review

Siena Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 50 shares — an estimated $8K sold.

Siena Capital first reported a position in JAZZ in Q1 2022 and held it in 2 quarters. The position peaked at $8K in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

Siena Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Siena Capital sold 50 Jazz Pharmaceuticals shares in Q3 2022, an estimated $8K.
Siena Capital first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 2 quarters.
Siena Capital's Jazz Pharmaceuticals position peaked at $8K in Q2 2022.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Siena Capital's 13F filing for Q3 2022, filed 2 Nov 2022.